Coherus Oncology, Inc.
CHRS
$0.7472
-$0.0204-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 229.25% | -40.84% | -5.09% | 10.67% | -92.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 229.25% | -40.84% | -5.09% | 10.67% | -92.88% |
| Cost of Revenue | 84.36% | -59.96% | -36.58% | 14.17% | -91.47% |
| Gross Profit | 469.16% | 191.59% | 19.51% | 8.10% | -94.42% |
| SG&A Expenses | -12.17% | -27.31% | -23.85% | -22.10% | -34.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.86% | -42.11% | -25.79% | -8.33% | -38.40% |
| Operating Income | 20.55% | 43.94% | 78.28% | 40.63% | 10.85% |
| Income Before Tax | 30.33% | 36.35% | 73.14% | 69.86% | 10.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.33% | 36.35% | 72.88% | 69.86% | 10.16% |
| Earnings from Discontinued Operations | -105.37% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -154.99% | 36.35% | 72.88% | 69.86% | 235.85% |
| EBIT | 20.55% | 43.94% | 78.28% | 40.63% | 10.85% |
| EBITDA | 20.28% | 44.64% | 83.03% | 42.60% | 11.89% |
| EPS Basic | -153.52% | 38.52% | 77.00% | 77.10% | 195.51% |
| Normalized Basic EPS | 19.69% | -187.35% | 75.64% | 99.48% | 44.01% |
| EPS Diluted | -153.52% | 34.87% | 77.24% | 77.10% | 195.04% |
| Normalized Diluted EPS | 19.69% | -187.35% | 75.64% | 99.48% | 44.01% |
| Average Basic Shares Outstanding | 2.76% | 3.52% | 17.88% | 31.57% | 42.24% |
| Average Diluted Shares Outstanding | 2.76% | 3.52% | 17.88% | 31.57% | 42.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |